Bionest

The SMA Market: Assessing the Unknowns

Challenges and opportunities in the field of spinal muscular atrophy, including how new disease-modifying therapies are likely to change SMA’s course over time.

Bionest

Neuromuscular Drug Development Summit

At the end of October, we attended the inaugural Neuromuscular Drug Development Summit. This new meeting brought together thought leaders from industry, academia, and the patient advocacy community to discuss scientific progress and issues affecting companies developing drugs for these mostly rare diseases.   Neuromuscular diseases — such as muscular dystrophies, motor neuron diseases, mitochondrial...